Meghan Heberton, M.D.

Harold C. Simmons Comprehensive Cancer Center

Dermatology - General
Oncodermatology

New Patient Appointment Accepting Virtual Visits or 214-645-2400

Biography

Meghan Heberton, M.D., is an Assistant Professor in the Department of Dermatology at UT Southwestern Medical Center and the Director of Oncodermatology at the Harold C. Simmons Comprehensive Cancer Center.

Dr. Heberton earned her medical degree at the UTHealth Houston McGovern Medical School. She completed residencies in internal medicine and dermatology at Washington University-affiliated Barnes-Jewish Hospital in St. Louis, Missouri, where she served as Chief Dermatology Resident.

Certified by the American Board of Internal Medicine and the American Board of Dermatology, she worked for three years at MD Anderson Cancer Center in Houston prior to joining the UT Southwestern faculty in 2022.

Dr. Heberton is the founder of the Oncodermatology Program at UT Southwestern. The clinic is housed in the Cancer Center Outpatient Building and designed to serve patients of the Simmons Cancer Center with skin concerns.

She treats a broad range of diagnoses, including:

Skin toxicities from cancer therapies like chemotherapy, targeted therapy, and immunotherapy
Post-radiation and surgical skin changes
Preventive skin exams in patients with cancer
Pre- and post-stem cell transplant care and graft versus host disease
General skin concerns

Dr. Heberton is passionate about partnering with patients and works closely with them as well as other members of the cancer treatment team to provide integrated, compassionate, and expert care.

She is a Fellow of the American Academy of Dermatology and a member of the Oncodermatology Society and the Medical Dermatology Society, as well as being an active on committees within those organizations.

Dr. Heberton has collaborated on multiple clinical trials, and she has delivered invited lectures and published numerous academic articles related to her areas of expertise. She also enjoys educating and mentoring residents and medical students.

Personal Note

When she’s not at work, Dr. Heberton enjoys pretending to be a chef and hiking in national parks.

Education & Training

Residency - Washington University in St. Louis School of Medicine (2016-2019), Dermatology
Residency - Washington University Barnes Jewish Hospital/ St. Louis Children's Hospital Consortium Program (2013-2016), Internal Medicine
Medical School - McGovern Medical School at the University of Texas Health Science Center at Houston (2009-2013)

Professional Associations & Affiliations

American Academy of Dermatology
Oncodermatology Society
Medical Dermatology Society

Honors & Awards

UTSW Dermatology Teaching Award 2024, UTSW Department of Dermatology
Chief Resident 2018-2019, Dermatology at Barnes-Jewish Hospital
Lewis R. Chase Research Award 2016, Barnes-Jewish Hospital
Jason Goldfeder Award for Excellence in the Medicine Clinic 2016, Barnes-Jewish Hospital
Internal Medicine Intern of the Year 2014, Barnes-Jewish Hospital

Books & Publications

Publications
- Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia.
  Sarlashkar P, Carr C, Heberton M, JAAD case reports 2024 Nov 53 60-62
- Erythema multiforme-like targetoid eruption in two patients treated with capivasertib for metastatic breast cancer.
  Keum H, Zhu JL, Heberton M, Vandergriff T, Dominguez AR, JAAD case reports 2024 Nov 53 79-82
- Epidermodysplasia Verruciformis and Vδ2 γδ T-cell Expansion in STK4 Deficiency.
  Ying W, Long X, Vandergriff T, Karnati H, Heberton M, Chen M, Wang X, Wysocki C, Kong XF, Journal of clinical immunology 2024 Aug 44 8 172
- Types and severity of cutaneous toxicities to BRAF inhibitors are drug-specific and discrete: A single-center cohort study.
  Sarlashkar P, Gill JG, Heberton M, Journal of the American Academy of Dermatology 2024 Jul
- Increased presentation for vitiligo cutaneous immune related adverse events in Hispanic patients.
  Momin ZK, Gill JG, Heberton M, Archives of dermatological research 2024 May 316 6 293
- Tumoral melanosis: A case series of patients with metastatic melanoma after systemic immunotherapy.
  Wix SN, Heberton M, Vandergriff TW, Yancey KB, Gill JG, JAAD case reports 2024 Mar 45 82-87
- Clinical Features and Outcomes of Black Patients with Melanoma.
  Wix SN, Brown AB, Heberton M, Adamson AS, Gill JG, JAMA dermatology 2024 Jan
- Lymphomatoid papulosis with DUSP22-IRF4 rearrangement: A case report and literature review.
  Niu N, Heberton MM, Tang Z, Aung PP, Nagarajan P, Curry JL, Prieto VG, Torres-Cabala CA, Cho WC, Journal of cutaneous pathology 2023 Mar
- Durvalumab-associated generalized morphea with overlapping vitiligo.
  Martel J, Cho WC, Runge JS, Patel AB, Tayar J, Woodman K, Hume CB, Curry J, Heberton M, JAAD case reports 2022 Dec 30 83-86
- A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes.
  Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, Heberton M, Journal of the American Academy of Dermatology 2022 Dec 87 6 1394-1395
- Pembrolizumab-induced rash in a patient with angiosarcoma.
  Qian J, Kubicki SL, Curry JL, Jahan-Tigh R, Benjamin R, Heberton M, Nelson KC, JAAD case reports 2022 Nov 29 21-24
- Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
  Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N, Leukemia research 2022 Aug 119 106884
- Pruritic papules in a longstanding tattoo.
  Yao C, Heberton M, JAAD case reports 2022 May 23 120-122
- Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
  Seervai RNH, Heberton M, Cho WC, Gill P, Murphy MB, Aung PP, Nagarajan P, Torres-Cabala CA, Patel AB, Ruiz-Bañobre J, Om A, Yamamoto T, Nikolaou V, Curry JL, Journal of cutaneous pathology 2022 May 49 5 472-481
- Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
  Starling CT, Messer AA, Kleiman A, McQuade JL, Glitza IC, Torres-Cabala CA, Heberton M, Dermatology online journal 2022 Mar 28 2
- Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients.
  Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022 Feb 30 2 989-994
- Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy.
  Seervai RNH, Cho WC, Chu EY, Marques-Piubelli ML, Ledesma DA, Richards K, Heberton MM, Nelson KC, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL, Journal of cutaneous pathology 2022 Jan 49 1 61-81
- Periorbital edema associated with alpelisib.
  Dao EA, George SJ, Heberton MM, Pacha O, Kovitz CA, Patel AB, Phillips RM, Cancer treatment and research communications 2022 32 100596
- Cutaneous Surgery Outcomes in Patients on Epidermal Growth Factor Receptor Inhibitors.
  Robinson MA, Patel AB, Wilmas KM, Thomas V, Heberton M, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2021 Nov 47 11 1519-1521
- Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies.
  Hanania HL, Pacha O, Heberton M, Patel AB, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2021 Jun 47 6 775-779
- Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma.
  McNally MA, Vangipuram R, Campbell MT, Nagarajan P, Patel AB, Curry JL, Heberton M, JAAD case reports 2021 Apr 10 82-84
- Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.
  Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT, Frontiers in oncology 2021 11 621591
- Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment.
  Duke TC, Nair R, Torres-Cabala C, Amaria RN, Keiser E, Miranda R, Iyer SP, Heberton M, JAAD case reports 2020 Dec 6 12 1264-1267
- Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study.
  Heberton MM, Tripathi S, Slade M, Trinkaus K, Romee R, Anadkat M, Journal of the American Academy of Dermatology 2020 Dec 83 6 1654-1658
- A case of unilateral extremity swelling.
  Heberton M, Nieman E, Jones H, JAAD case reports 2019 Aug 5 8 746-747
- Disseminated blastomycosis in a patient on pembrolizumab for metastatic melanoma.
  Ferguson I, Heberton M, Compton L, Keller J, Cornelius L, JAAD case reports 2019 Jul 5 7 580-581
- Metastatic Cutaneous Melanoma Presenting With Melanoma-Associated Retinopathy.
  Heberton M, Azher T, Council ML, Khanna S, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2019 Apr 45 4 606-607
- Decompressive hemicraniectomy with or without clot evacuation for large spontaneous supratentorial intracerebral hemorrhages.
  Esquenazi Y, Savitz SI, El Khoury R, McIntosh MA, Grotta JC, Tandon N, Clinical neurology and neurosurgery 2015 Jan 128 117-22

Clinical Focus

Oncodermatology